7 / 17
Page 21
Note:
S e p t e m b e r 2 0 - 2 1 , 2 0 1 8 | R o m e , I t a l y
Joint Event on
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
alliedacademies.comYEARS
Dermatology Congress 2018 & World Nephrology 2018
Archives of General Internal Medicine
|
ISSN: 2591-7951
|
Volume 2
2
nd
WORLD NEPHROLOGY AND THERAPEUTICS CONGRESS
DERMATOLOGY AND TRICHOLOGY
&
International Congress on
Diana Yonova, Arch Gen Intern Med 2018, Volume 2 | DOI: 10.4066/2591-7951-C5-014
NOVELTIES IN ADDITIVE MANUFACTURING
AND BIO-PRINTING
Diana Yonova
University Hospital “Lozenets”, Bulgeria
Background:
Influence of vitamin K2 treatment on some bone-related
markers in patients with chronic kidney diseases (ckd) on hemodialysis
treatment (HDT). Patients with CKD suffer from disturbed bone metabolism
and accelerated vascular calcification, particularly those on HDT. The
vitamin K-dependent matrix Gla protein (MGP) is one of the powerful
inhibitors of vascular calcification and Osteocalcin (OC) is a vitamin
K-dependent stimulator of osteoblasts activation, respectively improves
bone metabolism. HDT patients have high levels of the inactive form of MGP
(desphosphorylated-uncarboxylated-MGP, dp-uc-MGP) and higher serum
uncarboxylated OC (uc-OC), and may benefit from pharmacological doses of
vitamin K2 (menaquinone) to improve the calcification inhibitory activity of
MGP, to decrease uncarboxylated OC and to activate carboxylate one.
Materials &Methods:
To optimize the dose of menaquinone-7 (MK-7) for MGP
and OC activation, 55 patients on chronic HDT were recruited to randomly
receive 360 or 720 µg of MK-7 daily for 12 weeks. Dp-uc-MGP, uc-OC, sCa and
sP were measured at baseline and after 12 weeks. Dietary intake of vitamin
K1 and K2 was estimated based on a questionnaire.
Results:
Dp-uc-MGP correlated inversely with menaquinone intake (K2)
(p=0.025); uc-OC had a similar inverse correlation with MK-7 (K2) (p=0.033)
(supplementation dose dependently reduced dp-uc-MGP and uc-CT). The
levels decreased by 19.5% and 47% for dp-uc-MGP and by 22% and 49.6% for
uc-OC in the respective groups.
Conclusion:
HDT patients have high levels of inactive MGP and OC, possibly
related to a low serum vitamin K2. Pharmacological doses of MK-7 dose-
dependently reduces dp-uc-MGP and uc-OC. Menaquinone supplementation
may be a novel approach to prevent vascular calcifications in chronic
hemodialysis patients and to improve bone metabolism in CKD and HDT.
Diana Yonova has completed her specialty in Internal
Diseases in 1985 and in Nephrology – in 1987 year.
She has completed PhD 25 years ago in Medical Uni-
versity, Sofia, Bulgaria and postdoctoral studies at
2000/2001 year - in University Hospital “G Maranon”,
Madrid, Spain as a fellow of International Society of
Nephrology (ISN). She has been Head of the Dialysis
Center in Medical University, Sofia from 2008 to 2016
year. She has published more than 200 papers in Bul-
garian and international medical journals, and has
been participant in more than 250 presentations, lec-
tures and posters in national and international med-
ical symposiums and congresses. She is serving as
an Editorial Board Member in the National Journal of
Nephrology Dialysis and Transplantation for the year
2004.
yonovad@abv.bgBIOGRAPHY